Ezetimibe

Also known as Zetia and Ezetrol.

Latest news on ezetimibe

9 November 2026
Amgen’s Repatha shown cost‑effective and to lower long‑term CV events when used earlier

Data show early LDL‑C lowering with Repatha reduces major cardiovascular events and is cost‑effective for high‑risk patients without prior heart attack or stroke.

5 November 2026
Amgen: Repatha lowers heart attack risk 20% vs ezetimibe in large real‑world cohort

Real‑world analysis of 544,103 adults with ASCVD followed up to four years; comparative non‑statin outcomes evidence to inform treatment choices and LDL‑C goal attainment.

31 August 2026
Amgen: Repatha reduces all‑cause mortality in high‑risk primary prevention (VESALIUS‑CV)

Pre‑specified VESALIUS‑CV analysis shows evolocumab plus background therapy lowers deaths and major CV events in high‑risk adults without prior MI/stroke.

7 June 2026
Amgen: Repatha (evolocumab) cuts first major CV events 29% in high‑risk diabetes subgroup

VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.

28 March 2026
Amgen: Repatha cuts first major cardiovascular events 31% in high‑risk patients without significant atherosclerosis

VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.